San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.
DUBLIN, Dec. 22, 2014 /PRNewswire/ – Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced today that Rajiv De Silva, President and CEO, will present a corporate overview at the Goldman Sachs Healthcare CEOs Unscripted Conference on Tuesday, January 6, 2015 in Boston at 8:00 a.m. Eastern Time and at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 in San Francisco at 2:00 p.m. Pacific Time.
A live webcast and audio archive for both events will be available on the company’s website at www.endo.com . Click on Investor Relations, and then the link to the Event and Presentation. Participants should allow approximately five to ten minutes prior to the presentation’s start time to visit the site and download any streaming media software needed to listen to the Internet webcast.
Endo International plc is a global specialty healthcare company focused on improving patients’ lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic pharmaceutical, over the counter medications and medical device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at www.endo.com.
SOURCE Endo International plc
Research at Scripps helps explain health benefits attributed to chemical resveratrol.
SAN DIEGO and SAN FRANCISCO, Dec. 22, 2014 /PRNewswire/ – ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present and participate in moderated panel discussions at the upcoming Biotech ShowcaseTM taking place January 12-15, 2015 in San Francisco. The presentation details are as follows:
State of the Regenerative Medicine and Advanced Therapies Briefing
“Dose, Delivery, Data: Understanding the Three D’s of Advanced Therapy Drug Development”
Monday, January 12th at 9:05 a.m. PST
Monday, January 12th at 11:30 a.m. PST
“Type 1 Diabetes: Novel Therapies, Devices and Diagnostics on the Horizon”
Tuesday, January 13th at 8:00 a.m. PST
All of the presentations will take place at the Parc55 Wyndham San Francisco in Union Square. To register for the events or for more information, please visit Biotech Showcase’s website: http://www.ebdgroup.com/bts/program/index.php
Dr. Laikind will review recent progress with the company’s VC-01™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development. A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes, called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first implant was announced in October 2014.
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead product candidate VC-01 in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a
SOURCE ViaCyte, Inc.
Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery
SAN DIEGO, Dec. 22, 2014 /PRNewswire/ — GenomeDx Biosciences today announced that a new study showed that the Decipher Prostate Cancer Classifier, a genomic test for prostate cancer, was able to predict rapid metastatic disease in node-negative, high-risk men managed by radical prostatectomy without adjuvant therapy. Although rapid metastasis in men treated with radical prostatectomy is relatively uncommon, using tumor genomics to identify these men who have a highly lethal form of metastatic disease is an important advance. The study has been published online by the journal European Urology.
The findings highlight the significance of identifying the patients at highest risk of rapid metastasis for timely treatment after surgery:
Of men who had rapid metastasis within five years, while all initially had undetectable PSA after surgery and were indistinguishable by standard clinical and pathologic features, 50% developed bone metastasis by two years and 50% died of their disease by seven years after surgery.
Of men experiencing late metastasis, none died of their prostate cancer at seven years after surgery and the median time to metastasis was over nine years. “Clinical and pathological risk factors were not able to distinguish which among the patients at risk of recurrence in our cohort might develop rapid metastatic disease,” said Eric Klein, M.D., Chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic. “Identification of such patients is clinically relevant, as those at highest risk for rapid metastasis and death are mostly likely to benefit from earlier, more intensive therapy and inclusion in clinical trials of novel agents. Perhaps what is more important for the average patient treated with radical prostatectomy at our institution is the high negative predictive value of this genomic test. Our study suggests that a patient with genomic low risk, despite having adverse pathology findings, is likely best managed conservatively after surgery and may safely avoid radiation therapy and the associated adverse side-effects.” Dr. Klein is a paid consultant for GenomeDx Biosciences.
The study, titled “A Genomic Classifier Improves Prediction of Metastatic Disease Within Five Years After Surgery in Node-negative High-risk Prostate Cancer Patients Managed by Radical Prostatectomy Without Adjuvant Therapy,” evaluated 169 patients who had a preoperative PSA of greater than 20 ng/mL, a negative pathologic node, undetectable PSA following prostate surgery and did not have neoadjuvant or adjuvant therapy. Fifteen patients experienced rapid metastasis, defined as occurring within five years of surgery, and 34 had late metastasis, defined as occurring more than five years after surgery. When the Decipher results were applied, Decipher demonstrated the highest prediction of metastatic disease compared to the Stephenson and CAPRA-S nomograms, with an AUC of 0.77 compared to 0.75 and 0.72 respectively. In addition, integration of Decipher into the Stephenson nomogram resulted in an increased performance as measured by AUC of 0.79.
“The clinical utility of Decipher in this patient population may have the most impact, beyond nomograms, on identifying more patients who, despite having multiple adverse pathology findings after surgery, have a high probability of metastasis-free survival even when managed conservatively without adjuvant therapy,” said Elai Davicioni, Ph.D, founder and CSO of GenomeDx. “Further, this study showed that Decipher was able to better identify the few patients with a highly lethal form of metastatic disease who have the most to benefit from earlier, more intensive adjuvant therapy.”
About DecipherThe Decipher® Prostate Cancer Classifier directly measures a patient’s biological risk of developing metastatic prostate cancer. Based on a whole genome profile of a patient’s tumor, Decipher predicts the aggressiveness of a patient’s disease based on genomic information that is distinct from that provided by PSA and other clinical risk factors. Clinical studies have demonstrated that Decipher can accurately predict aggressive disease and help physicians make more informed treatment decisions for men with prostate cancer. Decipher was developed in partnership with the Mayo Clinic.
Decipher is covered multiple private insurance plans and is available to eligible US patients through their physicians. To learn more about Decipher please visit www.deciphertest.com.
About GenomeDx BiosciencesGenomeDx Biosciences is focused on transforming patient management by putting usable genomic information in the hands of patients and their physicians. GenomeDx has developed the Decipher® Prostate Cancer Classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. To learn more visit www.genomedx.com.
Media Contact:Ian StoneCanale Communications619email@example.com
SOURCE GenomeDx Biosciences
The Cystic Fibrosis (CF) Foundation’s big win in venture philanthropy can fuel constructive competition among companies developing innovative CF drugs, benefiting both patients and the healthcare…
[[Click headline to continue reading.]]
Acting President and CEO Jim Paulson shares his reflections about the institute’s accomplishments of the past year and his optimism for the future.
The technique, developed by the TSRI’s Deniz lab and UC San Diego colleagues, lays the groundwork for better understanding misfolding-prone proteins that cause illnesses such as Alzheimer’s, Parkinson’s and Huntington’s disease.
As proof-of-principle, a team from the Baran lab makes dozens of new chemical entities. The new method—which is extraordinarily robust—can be used to make pharmaceuticals, fabrics, dyes, plastics and other previously inaccessible materials.
This year TSRI scientists continued to make strides in their quest to understand the fundamental processes of life and to advance human health.
Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Companys presentation at the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, California, on January 12, 2015. The live webcast is scheduled to begin at 11:00 a.m. Pacific Time and will feature a brief overview of the company by Jay Flatley, Chief Executive Officer, followed by a question and answer session.